Growing evidence has demonstrated that the activation of the ERK1/2 pathway accelerated the proliferation of tumor cells, including oral cancer [23], nasopharyngeal cancer [24], and hepatoma cells [25]. This evidence concerns the gene MAPK3 and lip and oral cavity carcinoma.